18-19 novembre 2022

CONGRESSO ATBV 2022

Filmati dei lavori

 

I giornata

 

ABOVE AND BEYOND LDL CHOLESTEROL

Gaetano Maria De Ferrari, Maddalena Lettino

 

Optimal Use of Statins, Ezetimibe, and Bempedoic Acid in Clinical Practice – Paolo Calabrò

Evolutions of PCSK9 Inhibition – Giuseppe Musumeci

Icosapent ethyl is different than PolyUnsaturated Fatty Acids: Understanding REDUCE IT – Giuseppe Patti

The future is now: Lipoprotein (a) inhibition and more! – Alberico Catapano

Discussion and Take Home Messages

 

 

JOINT ATBV-ACVC SESSION: MANAGEMENT OF ANTITHROMBOTHIC
THERAPY IN CRITICALLY ILL PATIENTS

Ingo Ahrens, Maddalena Lettino

 

Antithrombothic Strategies in Patients with Mechanical Circulatory Support – Christophe Vendenbriele

Atrial Fibrillation in Critically Ill Patients – Kurt Huber

Discussion

 

 

SPOTLIGHT SESSION: ESTABLISHED AND EMERGING PARENTERAL
ANTIPLATELET AGENTS

Alberto Menozzi, Raffaele Piccolo

 

Cangrelor and Glycoprotein IIb/IIIa Inhibitors: Different Drugs, Different Roles – Leonardo De Luca

Future Pre-Hospital Strategies: Selatogrel and RUC-4 – Felice Gragnano

Discussion

 

 

II giornata

 

EVOLVING ANTITHROMBOTIC STRATEGIES IN PATIENTS WITH
ACUTE AND CHRONIC CORONARY SYNDROME: TOWARD
PERSONALIZED MEDICINE?

Claudio Fresco, Luigi Oltrona Visconti

 

Is Guided Antiplatelet Therapy Ready for Prime Time? – Davide Capodanno

Indication and Timing of P2Y12 Inhibitors Monotherapy After ACS – Leonardo Bolognese

Vascular dose of rivaroxaban: from evidence to pratcice – Marco Ferlini

Bridgining Antithrombothic Strategies in Patients with Coronary Stent Requiring Surgery – Giuseppe Musumeci

Discussion